Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV

L Taramasso, S Bonora, A Cingolani… - Journal of …, 2025 - academic.oup.com
Modern ART is evolving, allowing the use of new drug formulations and alternative routes of
administration to oral therapy. Long-acting (LA) cabotegravir and rilpivirine, the first fully …

Is Nonsustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug Levels?

P Thoueille, C Marzolini, M Guidi… - Clinical Infectious …, 2024 - academic.oup.com
TO THE EDITOR—We read with great interest the recent work by Gutiérrez et al [1], which
identified that a more advanced human immunodeficiency virus infection at antiretroviral …

Insights on Drug Levels and Non-Sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy

F Gutiérrez, M Fernández-González… - Clinical Infectious …, 2024 - academic.oup.com
TO THE EDITOR—We appreciate the opportunity to address the concerns raised by
Thoueille et al [1] regarding the higher rilpivirine (RPV) trough concentrations reported in our …

Efficacy, Safety and Retention in Care Among Adolescents and Youth With HIV on Long-Acting Injectable Cabotegravir/Rilpivirine Treatment: Real-World …

T Williams, J Unternaher, WLA Koay… - The Pediatric …, 2025 - journals.lww.com
Background: Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) can improve
adherence among adolescents and youth with HIV (AYHIV). We evaluated LAI CAB/RPV …

Transient Viremia Among People with HIV Receiving Injectable Cabotegravir Plus Rilpivirine

LF O'Connor, WLA Koay, J Unternaher… - AIDS Research and …, 2025 - liebertpub.com
Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) provides an effective
treatment option for people with HIV (PWH). Studies suggest that PWH on LAI CAB/RPV may …